NeuBase Therapeutics found using ticker (NBSE) have now 6 analysts covering the stock with the consensus suggesting a rating of ‘Strong_Buy’. The target price ranges between 18 and 13 with a mean TP of 15.67. Given that the stocks previous close was at 8.14 this now indicates there is a potential upside of 92.5%. The 50 day moving average now sits at 8.06 while the 200 day moving average is 8.32. The market cap for the company is $180m. Find out more information at: http://www.neubasetherapeutics.com
The potential market cap would be $347m based on the market concensus.
NeuBase Therapeutics, a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company’s proprietary peptide-nucleic acid antisense oligonucleotide (PATrOL) platform focuses on addressing Huntington’s disease (HD) and myotonic dystrophy, as well as other genetic disorders. Its lead programs include NT0100, a PATrOL-enabled therapeutic program for systemic administration to target the mutant expansion in the HD messenger ribonucleic acid (mRNA); and NT0200, a PATrOL-enabled therapeutic program for systemic administration to target the mutant expansion in the myotonic dystrophy type 1 disease mRNA. NeuBase Therapeutics is headquartered in Pittsburgh, Pennsylvania.
